Antiplasmodial activity of *Cocos nucifera* leaves in *Plasmodium berghei*-infected mice

Nicole M. Tayler¹ ² • Rosa De Jesús¹ • Rita Spadafora³ • Lorena M. Coronado¹ • Carmenza Spadafora¹

Received: 17 December 2019 / Accepted: 20 February 2020 / Published online: 9 March 2020
© The Author(s) 2020

Abstract *Plasmodium falciparum* (*P. falciparum*) malaria presents serious public health problems worldwide. The parasite’s resistance to antimalarial drugs has proven to be a significant hurdle in the search for effective treatments against the disease. For this reason, the study of natural products to find new antimalarials remains a crucial step in the fight against malaria. In this study, we aimed to study the in vivo performance of the decoction of *C. nucifera* leaves in *P. berghei*-infected mice. We analyzed the effectiveness of different routes of administration and the acute toxicity of the extract. Additionally, we determined the suppressive, curative and prophylactic activity of the extract. The results showed that the decoction of leaves of *C. nucifera* is most effective when administered intramuscularly to mice in comparison to intraperitoneal, subcutaneous and intragastric methods. We also found that organ signs of acute toxicity appear at 2000 mg/kg/day as evidenced by necropsy examination. Additionally, we found that the prophylactic effect of the extract is of 48% inhibition, however, there is no curative effect. Finally, in a 4-day suppressive assay, we found that the extract can inhibit the growth of the parasite by up to 54% at sub-toxic doses when administered intramuscularly.

Keywords *Plasmodium falciparum* • *Cocos nucifera* • Aqueous extract • Antiplasmodial • *Plasmodium berghei*

Introduction

The most dangerous form of malaria is caused by *Plasmodium falciparum* (*P. falciparum*) parasites which present serious health problems worldwide. For the year 2017, there were approximately 219 million cases of malaria worldwide, compared to 217 million cases in the previous year. There were approximately 435,000 deaths from malaria globally in 2017, compared to 451,000 estimated deaths in 2016. The highest disease burden is centered in Sub-Saharan Africa, with children less than 5 years of age being the most affected group (WHO 2018). To date, the most effective ways to control these parasitic illnesses have been the use of drugs to treat the diseases and insecticides to control their transmission. Resistance to chloroquine, and lately to artemisinin derivatives and insecticides, gives fresh impetus to the search for new agents (Achan et al. 2018).

This search has led scientists to examine microorganisms, animal fur and plants (Higginbotham et al. 2014; Martínez-Luis et al. 2012; Durant et al. 2014; Isaka et al. 2018; Schorderet Weber et al. 2019; Whitman et al. 2019) for signs of activity against various diseases. In Panama we can find one of the planet’s most uniquely biodiverse environments, rich in plant and animal species potentially useful for alternative medicine studies. As part of their conservation efforts, The National Association for the Conservation of Nature (ANCON) protects a private natural reserve in Punta Patiño, Darién. This area is
characterized by large extensions of coconut palm plantations of *Cocos nucifera* (*C. nucifera*).

The coconut tree has traditionally been used to treat several human diseases such as arthritis and asthma; and symptoms such as diarrhea and fevers; as a diuretic, and to treat malaria, among others (Lima et al. 2015). Several studies have described the traditional use of *C. nucifera* husk, water and inflorescence on mice and rats to address several pathologies (Naskar et al. 2011; Rinaldi et al. 2009; Renjith et al. 2013; Alviano et al. 2004; Omoboyowa et al. 2016). One study describes the use of *C. nucifera* leaf extracts as reducing amyloid-β(1-42) aggregation in transgenic Caenorhabditis elegans (Manalo et al. 2017). Another study describes the safety of *C. nucifera* leaf extracts in mice, however, it does not evaluate the effectiveness of these extracts on any pathology (Paul et al. 2012). Because we have previously reported the in vitro antiplasmodial activity of the water extract of leaves (Tayler et al. 2019), and because to our knowledge there are no rigorous studies which describe the use of the leaves of *C. nucifera* against *P. falciparum*, we decided to test its in vivo potential as an antimalarial.

Our work focused on evaluating the inoculation route, acute toxicity, hematological parameters and antiplasmodial activity exerted by the aqueous extract of *C. nucifera* leaves from the Punta Patiño Private Natural Reserve in mice infected with *Plasmodium berghei* parasites.

**Materials and methods**

**Ethics statement**

All experimental procedures were performed in accordance with the institutional guidelines from the Institutional Committee of Animal Use and Care (Comité Institucional de Cuidado y Uso de Animales-CICUA) under approval number CICUA-17-004.

The authors were permitted to collect *C. nucifera* samples by the owners of the reserve, the National Association for the Conservation of Nature (ANCON), a non-government organization and stakeholder of this study. No other permission was required for research purposes and the field studies did not involve any endangered species.

**Plant material**

Leaves of *C. nucifera* were collected from the Punta Patiño Natural Reserve in Darien, Panama. They were identified by a botanist and voucher samples of the leaves were deposited at the Herbarium of the Universidad de Panama with registry number 0111279. The extracts were prepared as described in previous work by Tayler et al. (Tayler et al. 2019). In brief, 15 g of leaves were cleansed using distilled water and delicate task wipes (Kimwipes™, Thermo Fisher Scientific, Waltham, MA, USA). After drying, leaves were cut into smaller pieces and macerated with a mortar and pestil. The leaves were placed into a sterile beaker, covered with 250 mL of distilled water, and boiled for 15 min. Afterwards, leaves were subsequently filtered through sterile 0.8 μm and 0.22 μm membranes (Nalgene® vacuum filtration system). To prepare the experimental samples, 250 μL of the extract were aliquoted into glass vials and concentrated to reach approximately 292 mg/mL. Samples were aliquoted and stored at 4 °C until use. As positive control in all tests, chloroquine (10 mg/Kg/day) was applied subcutaneously.

**Mice and parasites**

The tests used throughout these studies were carried out on female mice of the inbred line C57BL/6, of 7 weeks of age with average weights of 21.5 ± 0.5 g, produced and maintained in the animal facility of INDICASAT AIP at a temperature of 20 °C, with light cycles of 12 h light/12 h darkness. Mice were maintained under biological barrier conditions such as change of personal wardrobe, use of masks and gloves and sterilization of the bedding chips and food (121 °C/15 min). Mice were handled according to the regulations on the use of laboratory animals of INDICASAT AIP. The parasites used to produce the infection were *P. berghei* ANKA (chloroquine sensitive) which were maintained in mice by successive C57BL/6 mouse - mouse passages.

**Determination of route of administration**

Female mice of the consanguineous line C57BL/6 were inoculated through intraperitoneal injection with 200 μl of *P. berghei* parasites. Four days after inoculation, infected blood was extracted through cardiac puncture and used to inoculate test subjects. A total of 10 mice were divided into 5 groups of two mice each, which were identified by permanent tattooing. These groups were characterized as: intramuscular (IM) administration, subcutaneous administration (SC), intragastrical (IG) administration, untreated group (control) and a chloroquine treated group injected subcutaneously with a 10 mg/kg dose (positive control) (Sigma, St. Louis, Missouri, USA). Mice were inoculated intraperitoneally with approximately $1 \times 10^7$ of *P. berghei* parasites (Alger 2001) and treatment started 24 h later. The extract was administered at a dose of 100 mg/kg/day to each group using a 1 cc syringe (Nipro Medical Corporation, Bridgewater, NJ, USA) with a puncture at the respective site (IM and SC). Intragastric administration was performed using an oral gavage needle. The parasitemia
was monitored until no more parasites were observed in the chloroquine group. To examine the parasitemia, a cut of approximately 1 mm was made on the tail of each mouse and blood smears were obtained which were subsequently stained with Giemsa 1:10, and parasites counted under a light microscope (brand OLYMPUS model BH2), with an objective of 100×.

**Toxicity assays**

For the toxicity analysis, the OECD guideline on its acute toxic class method section for the testing of chemicals was followed (OECD 2002). After testing the suggested 2000 mg/kg/day dose, lower doses of 1000 and 750 mg/kg/day were also analyzed. Three experimental groups of 5 mice each were formed, with each of the concentrations above. A control group was treated with only the vehicle, which was sterile water. The chloroquine control group was treated with 10 mg/kg/day of drug. Another control group was that of untreated mice. The extract was administered via IM for 4 days for each of the concentrations. Animals were observed for gross signs of toxicity (lacrimation, hair erection and reduction in their motor and feeding activities) 4 h after the administration of the extract, then daily for 16 days to assess safety of the extract. All animals were retro-orbitally sampled for hemoglobin, hematocrit, mean corpuscular volume and white cell counts in three moments: prior to administration of the extract, 8 and 16 days after administration. The blood work was performed by the Laboratory of the School of Veterinary Science, University of Panama, Panama. Results are average values per groups (controls and treated) for each dose at day 1 (beginning of treatment), day 8 and day 16 (end of the experiment). The mice were weighed daily for 8 days and one final time 16 days after administration. At this point, the animals were sacrificed by overdose of the ketamine/xylazine anesthetic mixture (normal dose: 50-150/5-15 mg/kg body weight).

**4-Day suppressive test**

For the suppressive test, we followed the protocol by Al-Adhroey et al. (2011) with some modifications. Five groups of five mice each were formed; two groups were experimental, with 500 and 750 mg/kg/day of the extract and three control groups: one with only the vehicle (sterile water) all injected intramuscularly, one untreated and a group treated with subcutaneous chloroquine. Mice were inoculated with approximately $1 \times 10^7$ *P. berghei* parasites and 72 h post infection, treatment was started (D1) via IM and continued for an additional 5 days (D5). Blood smears were obtained daily, stained with Giemsa 1:10 and infected parasites were counted under a light microscope, with an objective of 100×. The antimalarial activities of the extract were compared to both control groups treated with only the vehicle and the reference groups treated with the standard drug (chloroquine). Mean survival time (days) was evaluated over a 16-day period.

**Curative test**

For the curative test, we followed the protocol by Al-Adhroey et al. (2011) with some modifications. Five groups of five mice each were formed; two groups were experimental, with 500 and 750 mg/kg/day of the extract and three control groups: one with only the vehicle, another of untreated animals and a chloroquine-treated group. Mice were inoculated with approximately $1 \times 10^7$ *P. berghei* parasites intraperitoneally and the treatment with the extract was continued for an additional 3 days (4 days total). The antimalarial activities of the extract were compared to control groups treated with only sterile water. Parasitemia was analyzed using Hoechst 33342 staining and flow cytometry analysis gated on the region of erythrocyte population as explained in another section below.

For all assays, chemosuppression was calculated with the following formula (Angeles et al. 2005):
Supression = 
\[ \left( \frac{\text{Untreated group mean parasitemia} - \text{Treated group mean parasitemia}}{\text{Untreated group mean parasitemia}} \right) \times 100 \]

Quantification of parasitemia using flow cytometry

Parasitemia was obtained as described in Tayler et al. (2019). Briefly, blood samples were treated with Hoechst 33342 (Invitrogen, USA) at 2 μg/mL and incubated for 30 min while protected from light. Additionally, background staining of an uninfected red blood sample was always performed (Spadafora et al. 2010) and used to define the population of red blood cells using FSC/SSC to be gated for all samples. Debris and other stained cellular populations were ungated. Acquisition was performed with a UV laser on a PARTEC CyFlow Space cytometer (Görlitz, Germany).

Statistics

All data was analyzed using the software GraphPad (Prism, California, USA), performing analyses of variance. Significant differences between groups were determined using Bonferroni’s test. A \( p \leq 0.05 \) was considered significant.

Results

Determination of route of administration

The results of testing different routes of administration of the extract determined that the most effective route was intramuscular (IM), since even though the weight of the mice decreased for all of the different treatments, the mice treated intramuscularly with the extract were the ones whose weight decreased the least (−0.7 g), as shown in Fig. 1. With respect to parasitemia, mice given extracts via IM also had the lowest percentage of parasitemia (1.35%) at day 7, of all the extract-treated groups (Table 1).

Toxicity assays

In the group of mice given the concentration of 2000 mg/kg/day, 2 of the 5 mice died; which prompted the testing of two other lower dosages for acute toxicity (1000 and 750 mg/kg/day). In these other two groups no mice died and they survived until day 16 on which euthanasia was performed. In relation to weight, it was observed that no significant weight was lost relative to the controls at any of the three concentrations tested. With regard to the blood parameters, mice given the extract at 2000 mg/kg of weight had lower hematocrit and hemoglobin values than controls throughout the experiment. Mice given the extract at 1000 and 750 mg/kg of weight had normal values until the 8th day of treatment; however, all values for hematocrit and hemoglobin were lower than controls at day 16. All mice challenged with every concentration tested had values within the normal range of mean corpuscular volume, except for those treated with 750 mg/kg/day on Day 16 (VCM) (Table 2).

4-Day suppressive test

For the trials related to the 4-day suppressive test, treatments with 500 and 750 mg/kg/day of the extract were analyzed. The mean parasitemia on day 4 after infection was 11.8% ± 8.5 for 500 mg/kg/day and 7.4% ± 4.5 for 750 mg/kg/day. The range value for the control was 24.0 ± 1.2 to 16.1 ± 2.0. The percentage chemosuppression of the parasites was 51% for 500 mg/kg/day and 54% for 750 mg/kg/day. The daily suppressive effect can be observed in Fig. 2. Moreover, the mice infected with P. berghei parasites exhibited no signs of distress, such as weight loss, diminished exploratory behavior, hunched posture or unresponsiveness during the full length of the assay.

Curative test

The parasitemia percentage on day 5 in mice infected and treated with 500 and 750 mg/kg/day was 42.80 ± 4.10 and 38.73 ± 7.46, respectively, while the untreated group had a percentage parasitemia of 39.08 ± 6.65, and that of the chloroquine-treated group was 1.64 ± 0.23. From the point of view of chemosuppression of the parasites, the mice treated with 500 and 750 mg/kg/day presented an inhibition of −9.51% and 0.91%, whereas those treated with chloroquine had 95.81% (Fig. 3).

Fig. 1 Weight of P. berghei infected mice by different inoculation routes. The graph represents the mean of two mice in each of the groups. IM, intramuscular; SC, subcutaneous; IG, intragastric; CQ, Chloroquine and control (untreated)
Table 1  Parasitemia of *Plasmodium berghei* infected mice according to route of administration

| Inoculation routes | Days | IM  | SC   | IG   | CQ   | UT   |
|--------------------|------|-----|------|------|------|------|
|                    | 1    | 0.10 ± 0.00 | 0.47 ± 0.00 | 0.40 ± 0.00 | 0.47 ± 0.00 | 0.60 ± 0.00 |
|                    | 2    | 0.10 ± 0.07 | 1.67 ± 0.85 | 1.6 ± 0.85  | 0.03 ± 0.31 | 2.29 ± 1.20 |
|                    | 3    | 0.00 ± 0.00 | 7.30 ± 3.98 | 8.6 ± 4.95  | 0.10 ± 0.05 | 9.80 ± 5.31 |
|                    | 4    | 0.10 ± 0.07 | 8.95 ± 1.17 | 9.3 ± 0.49  | 0.10 ± 0.00 | 12.00 ± 1.56|
|                    | 5    | 0.10 ± 0.00 | 4.54 ± 3.12 | 16.00 ± 4.74| 0.00 ± 0.07 | 15.00 ± 2.12 |
|                    | 6    | 0.80 ± 0.49 | 6.10 ± 1.10 | 22.00 ± 4.24| 0.00 ± 0.00 | 21.00 ± 4.24 |
|                    | 7    | 1.35 ± 0.39 | 7.91 ± 1.28 | 37.00 ± 10.61| 0.00 ± 0.00 | 36.00 ± 10.61|

Table 2  Blood test values of uninfected mice treated with the decoction of *Cocos nucifera* leaves at day 1, day 8, and day 16 post treatment. Normal values are placed below each parameter title.

| Parameter                  | Day 1 | Day 8 | Day 16 |
|----------------------------|-------|-------|--------|
|                            |       |       |       |
| Hematocrit (%)             |       |       |       |
| 33–48%                     |       |       |       |
| Control                    | 31.9 ± 1.22 | 32.2 ± 0.35 | 32.7 ± 0.85 |
| Treated                    | 35.32 ± 2.25 | 17.75 ± 15.54 | 33.25 ± 2.47 |
| Hemoglobin (g/dL)          |       |       |       |
| 10–16                      |       |       |       |
| Control                    | 9.73 ± 1.7 | 10.67 ± 0.12 | 9.85 ± 1.34 |
| Treated                    | 11.66 ± 0.86 | 5.90 ± 5.16  | 11.05 ± 0.78 |
| MCV (fl/red cell)          |       |       |       |
| 42.3–55.2                  |       |       |       |
| Control                    | 50.23 ± 2.03 | 51.10 ± 0.40 | 50 ± 1.84 |
| Treated                    | 48.26 ± 2.3 | 61.15 ± 13.61 | 53.2 ± 1.84 |

Parameter                  | Day 1 | Day 8 | Day 16 |
|----------------------------|-------|-------|--------|
|                            |       |       |       |
| Hematocrit (%)             |       |       |       |
| 33–48%                     |       |       |       |
| Control                    | 31.5 ± 1.7 | 26.4 ± 5.86 | 26.4 ± 5.86 |
| Treated                    | 34.54 ± 2.62 | 28.54 ± 4.99 | 28.54 ± 4.99 |
| Hemoglobin (g/dL)          |       |       |       |
| 10–16                      |       |       |       |
| Control                    | 10.3 ± 0.35 | 8.77 ± 1.98 | 8.77 ± 1.98 |
| Treated                    | 11.5 ± 0.86 | 9.48 ± 1.69 | 9.48 ± 1.69 |
| MCV (fl/red cell)          |       |       |       |
| 42.3–55.2                  |       |       |       |
| Control                    | 48.33 ± 2.5 | 47.7 ± 3.42 | 47.7 ± 3.42 |
| Treated                    | 48.72 ± 1.33 | 50.24 ± 3.7 | 50.24 ± 3.7 |

Parameter                  | Day 1 | Day 8 | Day 16 |
|----------------------------|-------|-------|--------|
|                            |       |       |       |
| Hematocrit (%)             |       |       |       |
| 33–48%                     |       |       |       |
| Control                    | 28.57 ± 6.54 | 23.33 ± 0.58 | 32.2 ± 0.35 |
| Treated                    | 28.76 ± 3.37 | 20.74 ± 8.88 | 21.96 ± 5.03 |
| Hemoglobin (g/dL)          |       |       |       |
| 10–16                      |       |       |       |
| Control                    | 9.47 ± 2.16 | 7.73 ± 0.23 | 10.67 ± 0.12 |
| Treated                    | 9.58 ± 1.16 | 6.88 ± 2.96 | 7.28 ± 1.68 |
| MCV (fl/red cell)          |       |       |       |
| 42.3–55.2                  |       |       |       |
| Control                    | 50.23 ± 2.03 | 50.63 ± 1.70 | 51.1 ± 0.4 |
| Treated                    | 52.24 ± 2.94 | 51.52 ± 1.5 | 39.10 ± 12.2 |
Prophylactic test

At the end of treatment, the parasitemia percentage in infected mice treated with 500 and 750 mg/kg/day was 30.16 ± 5.03 and 23.28 ± 12.89, respectively (Fig. 4). The untreated group had a percentage parasitemia of 42.25 ± 7.89, whereas that of the chloroquine-treated control was 6.95 ± 1.84. The percentage chemosuppression of parasites in mice treated with 500 and 750 mg/kg/day was 28.60% and 44.91%, whereas that of the treatment with chloroquine was 83.56%.

Discussion

We carried out experiments to test the antimalarial activity of the extract from the leaves of *C. nucifera* on mice infected with *P. berghei* parasites, examining the routes of administration, the acute toxicity and different assays to determine its antiplasmodial effects.

The IM-treated mice were less susceptible to weight loss when compared with the other two routes of administration, oral and subcutaneous. Additionally, there was a greater antiplasmodial effect in these animals when compared to those treated subcutaneously and intragastrically. The latter administration of the extract involves the drug being subjected to the stomach acids which may cause it to be degraded (Levine 1970). Besides, using a gavage administration probably affected the animals’ ability to eat properly, resulting in weight loss, while subcutaneous administration may hinder the extract from reaching circulation and may not act against the parasites since the rate of absorption in this route is lower than intramuscular administration (Simmons and Brick 1970).

Our results for the acute toxicity assay showed that the extract presented signs of toxicity at the maximum concentration used (2000 mg/kg/day) when administered intramuscularly. In the group treated with the extract, two of the five mice died, with deaths beginning on the 6th day, suggesting that the dose at which half of the population dies (LD₅₀) lies slightly beyond 2000 mg/kg/day, since no animals died at 1000 mg/kg/day. Blood analysis of hematocrit and hemoglobin levels in all groups remained generally within the normal values up until day 8, when the three concentrations used apparently caused the hemoglobin to fall below the lower normal limit. This trend continued until day 16 suggesting that the extract negatively affects the integrity of red blood cells if used for periods longer than 8 days. Further experiments should monitor these levels more closely to determine the effects on hematocrit and hemoglobin parameters of the mice on a daily basis. Additionally, mean cell volume (MCV) parameters were analyzed in all groups. MCV is a measure
of the size of red blood cells and low values (normal reference range is typically 42.3–55.2 fl/red cell) are indicative of microcytic anemia (Dasgupta 2015). This parameter was found to be normal after inoculating the extract in all treated groups, indicating that, while the extract affects hemoglobin and hematocrit levels after the first 8 days, the size of the RBCs remains unaffected for extended periods of treatment.

At concentrations of 500 and 750 mg/kg/day, the leaf extract was able to exert a parasite chemosuppression of 51% and 54%, respectively. The slightly higher activity achieved at 750 mg/kg/day suggests that this extract has a moderate suppressive activity (Deharo et al. 2001). Tests achieved at concentrations between 750 and 1000 mg/kg/day should be explored to improve chemosuppression, but avoiding the slight toxicity found in the mice at 1000 mg/kg/day.

The extract does not show any curative effect when tested at concentrations of 500 and 750 mg/kg/day on P. berghei—infected mice. Nonetheless, in the prophylactic test, the extract at 500 and 750 mg/kg/day showed a dose-dependent activity against the parasite with P. falciparum inhibitory percentages of 28.60% and 44.91%, respectively. For a comparison with a classic anti-malarial drug, the use of chloroquine before infection was 83.56% efficient in stopping the infection.

Different products from the coconut plant have been studied extensively for their medicinal properties (Roopan 2016). Research has demonstrated the presence of metabolites such as polyphenols, glycosides, steroids, alkaloids, terpenoids, and others which could be responsible for those activities (Renjith et al. 2013; Manalo et al. 2017; Oliveira et al. 2009; Singla et al. 2011; Soumya et al. 2014). More specifically, the husk extracts of C. nucifera have shown to have antiplasmodial properties when tested in vitro and in vivo (Adebayo et al. 2012; Adebayo et al. 2013; Balogun et al. 2014; Angeles et al. 2005).

Previous research by our group (Taylor et al. 2019) demonstrated the presence of flavan-3-ols (epicatechin), flavones (catechin derivatives, isoorientin, apigenin, vitexin, isovitexin, and luteolin) in the leaves of C. nucifera from Punta Patiño, Panama, and the in vitro antiplasmodial activity of a water decoction of these leaves was described.

Flavonoids are phenolic compounds and one of the most common secondary metabolites found in plants. Flavonoids such as acacetin, apigenin, baicalin, chrysins, genistein, kaempferol, luteolin, among many others have been identified to possess antimalarial activity (Lehane and Saliba 2008). Additionally, compounds from the catechin family have been involved in antimalarial action (Sannella et al. 2007).

Fatty acid synthesis is of utmost importance in the development of malarial parasites. They are needed for parasite membrane and lipid body biogenesis (Palacpac et al. 2004) and they are used for the anchorage of parasite membrane proteins through glycosylphosphatidylinositol moieties (Gilson et al. 2006). There are three important enzymes involved in the fatty acid biosynthesis of P. falciparum, namely 3-hydroxyacyl-[acyl-carrier-protein] dehydratase (FabZ), 3-oxoacyl-[acyl-carrier-protein] reductase (FabG), and Enoyl-[acyl-carrier-protein] reductase [NADH] (FabI) (Tasdemir et al. 2006). In a study from Tasdemir et al. (2006) it was demonstrated that the flavonoids belonging to the gallic acid esters of catechins were the most active compounds against the parasite. They performed kinetic analyses using luteolin and (-)-catechin gallate as model compounds and revealed that FabZ was inhibited competitively. FabG was inhibited in a noncompetitive manner, whereas both compounds behaved as tight-binding noncompetitive inhibitors of FabI. Additionally, these polyphenols showed in vitro activity against chloroquine-sensitive (NF54) and -resistant (K1) P. falciparum strains in the low to submicromolar range (Tasdemir et al. 2006). Furthermore, in the presence of catechins from green tea and other important plant polyphenols, the inhibitory effect of triclosan binding to FabI from P. falciparum was potentiated (Sharma et al. 2007). The heightened binding of triclosan because of the high affinity of catechins was furthermore explained by molecular modeling studies based on flavonoids luteolin, quercetin, fistein, (-)-catechin gallate, and others (Banerjee et al. 2008). Modelling also correlated with the activity of luteolin against chloroquine-sensitive and chloroquine-resistant strains of P. falciparum, following in silico studies where it was shown that luteolin had good binding affinity against dihydrooroorate dehydrogenase (PiDHODH) and plasma membrane P-type cation translocating ATPase (PiATP4), two enzymes needed for the survival of the parasite. In vitro testing confirmed the finding showing low micromolar activity against P. falciparum. The flavonoids were found in the juice of Citrus species used traditionally for the treatment of malaria-associated fevers (Gogoi et al. 2019).

Several studies describe how catechin-related compounds such as epigallocatechin-3-gallate (EGCG) and epicatechin gallate (ECG) show moderate antiplasmodial effects. In a study by Sannella et al. (2007), a crude extract, as well as EGCG and ECG from green tea leaves, were found to strongly inhibit the growth of P. falciparum parasites in vitro. Additionally, they found that these catechins were able to potentiate the effect of artemisinin when used in combination against malaria parasites (Sannella et al. 2007).

The presence of flavan-3-ols (epicatechin), flavones (catechin derivatives, isoorientin and luteolin, among many others) could help explain the parasitemia reduction of P. berghei-infected mice tested in this study. It is clear, from
the chemosuppression percentages of 51% and 54% in a 4-day suppressive assay, in addition to a moderate prophylactic activity, that our crude extract from *C. nucifera* possesses antimalarial properties. Acute toxicity assays, however, showed a slight harming effect of this extract on hematocrit and hemoglobin parameters for the group which showed 54% chemosuppression. Even with this finding, the extract from *C. nucifera* leaves is a candidate for further analysis using a bioassay-guided isolation of compounds and/or fractions selected from the whole decoction. In addition, it would be valuable to determine the combinatorial effect this extract, and/or its compounds, could have on malaria parasites when paired with standard drugs. These approaches could result in new candidates and/or structures for drug development against human malaria.

**Acknowledgements** The authors would like to give thanks to Daniel Garcia for assistance with the extract preparations. NMT was funded by the Secretaria Nacional de Ciencia, Tecnologia e Innovacion (SENACYT) and the Instituto para la Formacion y Aprovechamiento de los Recursos Humanos (IFARHU)-Panama. CS was funded by a SENACYT FID2017-095 grant and partially by funds from the National System of Research (SNI).

**Compliance with ethical standards**

**Conflict of interest** The authors declare that they have no conflict of interests.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

Achan J, Mweigwa J, Edwin CP, D’Alessandro U (2018) Malaria medicines to address drugresistance and support malaria elimination efforts. Expert Rev Clin Pharmacol 11(1):61–70. https://doi.org/10.1080/17512433.2018.1387773

Adebayo J, Goulart Sant’Ana AE, Krettili A (2012) Evaluation of the antiplasmodial and cytotoxicity potentials of husk fiber extracts from *Cocos nucifera*, a medicinal plant used in Nigeria to treat human malaria. Hum Exp Toxicol 31(3):244–249. https://doi.org/10.1177/0960327111424298

Adebayo JO, Balogun EA, Malomo SO, Soladoye AO, Olatunji LA, Kolawole OM, Oguntoye OS, Babatunde AS, Akinola OB, Aguier AC, Andrade IM, Souza NB, Krettili AU (2013) Antimalarial activity of *Cocos nucifera* husk fibre: further studies. Evid Based Complement Altern Med 2013:742476. https://doi.org/10.1155/2013/742476

Al-Adhroey AH, Nor ZM, Al-Mekhlafi HM, Amran AA, Mahmud R (2011) Evaluation of the use of *Cocos nucifera* as antimalarial remedy in Malaysian folk medicine. J Ethnopharmacol 134(3):988–991. https://doi.org/10.1016/j.jep.2011.01.026

Alger J (2001) Densidad Parasitaria en Malaria: métodos de Determinación y su Interpretación. Rev Med Hond 69:118–120

Alviano DS, Rodrigues KF, Leitão SG, Rodrigues ML, Matheus ME, Fernandes PD, Antonioli AR, Alviano CS (2004) Antinociceptive and free radical scavenging activities of *Cocos nucifera*. (Palmae) husk fiber aqueous extract. J Ethnopharmacol 92(2–3):269–273. https://doi.org/10.1016/j.jep.2004.03.013

Angeles JGC, Laurena AC, Tecson-Mendoza EM (2005) Extraction of genomic DNA from the lipids-, polysaccharide-, and polyphenol-rich coconut (*Cocos nucifera* L.). Plant Mol Biol Report 23(3):297–298. https://doi.org/10.1007/BF02772760

Balogun EA, Malomo SO, Adebayo JO, Ishola AA, Soladoye AO, Olatunji LA, Kolawole OM, Oguntoye SO, Babatunde AS, Akinola OB (2014) In vivo antimalarial activity and toxicological effects of methanolic extract of *Cocos nucifera* (Dwarf red variety) husk fibre. J Integr Med 12(6):504–511. https://doi.org/10.1016/S2095-4964(14)60054-6

Banerjee T, Sharma SK, Surolhai N, Surolhai A (2008) Epigallocatechin gallate is a slow-tight binding inhibitor of enoyl-ACP reductase from *Plasmodium falciparum*. Biochem Biophys Res Commun 377(4):1238–1242. https://doi.org/10.1016/j.bbrc.2008.10.135

Dasgupta A (2015) Chapter 6-Mean corpuscular volume and carbohydrate-deficient transferrin as alcohol biomarkers. In: Dasgupta A (ed) Alcohol and its biomarkers-clinical aspects and laboratory determination. Elsevier, Amsterdam, pp 139–162. https://doi.org/10.1016/B978-0-12-800339-8.00006-7

Deharo E, Bourdy G, Quenoce C, Muñoz V, Ruiz G, Sauvain M (2001) A search for natural bioactive compounds in Bolivia through a multidisciplinary approach. Part V. Evaluation of the antimalarial activity of plants used by the Tacana Indians. J Ethnopharmacol 77(1):91–98. https://doi.org/10.1016/S0378-8741(01)00027-0

Durant AA, Rodríguez C, Herrera L, Almanza A, Santana AI, Spadafora C, Gupta MP (2014) Anti-malarial activity and HS-SPME-GC-MS chemical profiling of Plinia cerrocampanensis leaf essential oil. Malar J 13(1):18–26. https://doi.org/10.1186/1475-2875-13-18

Gilson PR, Nehil T, Vukcevic D, Moritz RL, Sargeant T, Speed TP, Schofield CR, Crabb BS (2006) Identification and stoichiometry of glycosylphosphatidylinositol-anchored membrane proteins of the human malaria parasite *Plasmodium falciparum*. Mol Cell Proteomics 5(7):1286–1299. https://doi.org/10.1074.mcp.M600035-MCP200

Gogoi N, Chetia D, Gogoi B, Das A (2019) Multiple-targets directed screening of flavonoid compounds from citrus species to find out antimalarial lead with predicted mode of action: an in silico and whole cell-based in vitro approach [published online ahead of print, 2019 Dec 25]. Curr Curr Aided Drug Des. https://doi.org/10.2174/1573409916666191226103000

Higginbotham S, Wong WR, Linington RG, Spadafora C, Iturrado L, Higginbotham S, Wong WR, Linington RG, Spadafora C, Gilson PR, Nebl T, Vukcevic D, Moritz RL, Sargeant T, Speed TP, Schofield CR, Crabb BS (2006) Identification and stoichiometry of glycosylphosphatidylinositol-anchored membrane proteins of the human malaria parasite *Plasmodium falciparum*. Mol Cell Proteomics 5(7):1286–1299. https://doi.org/10.1074.mcp.M600035-MCP200

Isaka M, Chinhanom P, Mayteeworakoon S, Laetong K, Chowong W, Cheoeylin R (2018) Lanostane triterpenoids from cultivated fruiting bodies of the basidiomycete *Ganoderma australae*. Nat Prod Res 32(9):1044–1049. https://doi.org/10.1080/14786419.2017.1378208

Lehane AM, Saliba KJ (2008) Common dietary flavonoids inhibit the growth of the intraerythrocytic malaria parasite. BMC Research Notes 1:26. https://doi.org/10.1186/1756-0500-1-26
Levine RR (1970) Factors affecting gastrointestinal absorption of drugs. Am J Dig Dis 15(2):171–188. https://doi.org/10.1007/BF02235648

Lima EBC, Sousa CNS, Meneses LN, Ximenes NC, Santos Júnior MA, Vasconcelos GS, Lima NB, Patrocinio MC, Macedo D, Vasconcelos SM (2015) Cocos nucifera (L.) (arecaceae): A phytochemical and pharmacological review. Brazilian J Med Biol Res 48(11):953–964. https://doi.org/10.1590/1414-431X20154773

Manalo R, Silvestre M, Barbosa A, Medina P (2017) Coconut (Cocos nucifera) ethanolic leaf extract reduces Amyloid-β (1-42) aggregation and paralysis prevalence in transgenic caenorhabditis elegans independently of free radical scavenging and acetylcholinesterase inhibition. Biomedicines 5(2):21–33. https://doi.org/10.3390/biomedicines50200017

Martínez-Luis S, Cherigo L, Arnold E, Spadafora C, Gerwick WH, Cubilla-Rios L (2012) Antiparasitic and anticancer constituents of the endophytic fungus Aspergillus sp. strain F1544. Nat Prod Commun 7(2):165–168. https://doi.org/10.1177/1934578X1200700207

Naskar S, Mazumder UK, Pramanik G, Gupta M, Kumar RB, Bala A, Islam A (2011) Evaluation of antihyperglycemic activity of Cocos nucifera Linn. on streptozotocin induced type 2 diabetic rats. J Ethnopharmacol 138(3):769–773. https://doi.org/10.1016/j.jep.2011.10.021

OECD (2002) Test No. 423: Acute Oral toxicity—acute toxic class 6 rats. OECD Publishing, Paris. https://doi.org/10.1787/9789264071001-en

Oliveira LMB, Bevilacqua CML, Costa CTC, Macedo ITF, Barros RS, Rodrigues ACM, Camurc¸a-Vasconcelos AL, Morais SM, Lima YC, Vieira LS, Navarro AM (2009) Anthelmintic activity of Cocos nucifera L. against sheep gastrointestinal nematodes. Vet Parasitol 159(1):55–59. https://doi.org/10.1016/j.vetpar.2008.10.018

Omoboyowa D, Obasi N, Otuchristian G, Danladi G, Okon M (2016) Protective effect of methanol stem bark extract of Cocos nucifera on paracetamol-induced hepatotoxicity in adult wistar rats. Int J Trop Dis Heal 11(4):1–10. https://doi.org/10.9734/IJTDH/2016/21787

Palpacuc NM, Hiramine Y, Mi-ichi F, Torii M, Kita K, Hiramatsu R, Horii T, Mitamura T (2004) Development-stage-specific triacylglycerol biosynthesis, degradation and trafficking as lipid bodies in Plasmodium falciparum-infected erythrocytes. J Cell Sci 117(Pt 8):1469–1480. https://doi.org/10.1242/jcs.009988

Paul N, Roy R, Bhattacharya S, Biswas M (2012) Acute and sub-chronic toxicity study of Cocos nucifera leaf extracts in mice. J Adv Pharm Edu Res 2(2):74–81

Renjith RS, Chikkam Rajamohanan T (2013) Cytoprotective, antihyperglycemic and phytochemical properties of Cocos nucifera (L.) inflorescence. Asian Pac J Trop Med 6(10):804–810. https://doi.org/10.1016/S1995-7645(13)60142-X

Rinaldi S, Silva DO, Bello F, Alviano CS, Alviano DS, Matheus ME, Fernandes PD (2009) Characterization of the antinoceptive and anti-inflammatory activities from Cocos nucifera L. (Palmae). J Ethnopharmacol 122(3):541–546. https://doi.org/10.1016/j.jep.2009.01.024

Roopan SM (2016) An overview of phytoconstituents, biotechnological applications, and nutritive aspects of coconut (Cocos nucifera). Appl Biochem Biotechnol 179(8):1309–1324. https://doi.org/10.1007/s12010-016-2067-y

Sannella AR, Messori L, Casini A, Vincieri FF, Bilia AR, Majori G, Severini C (2007) Antimalarial properties of green tea. Biochem Biophys Res Commun 353(1):177–181. https://doi.org/10.1016/j.bbrc.2006.12.005

Schorderet Weber S, Kaminski KP, Perret JL, Leroy P, Mazunov A, Peitsch MC, Ivanov NI, Julia H (2019) Antiparasitic properties of leaf extracts derived from selected Nicotiana species and Nicotiana tabacum varieties. Food Chem Toxicol 132:110660. https://doi.org/10.1016/j.fct.2019.110660

Sharma SK, Parasuraman P, Kumar G, Surolia N, Surolia A (2007) Green tea catechins potentiate trichlosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR). J Med Chem 50(4):765–775. https://doi.org/10.1021/jm061154d

Simmons ML, Brick JO (1970) The laboratory mouse. In: Hollaender A (ed) The laboratory mouse: selections and management. Prentice Hall-Inc, Englewood, pp 127–129

Singla RK, Jaishwal N, Bhat GV, Jagani H (2011) Antioxidant and antimicrobial activities of Cocos Nucifera Linn. (Arecalesaceae) endocarp extracts. Ind J Pharm Sci 1(4):354–361

Soumya V, Muzib YL, Venkatesh P, Harirprash K (2014) GC-MS analysis of cocus nucifera flower extract and its effects on heterogeneous systems of polyglycic ovarian disease in female wistar rats. Chin J Nat Med 12(9):677–684. https://doi.org/10.1016/S1875-5364(14)60103-5

Spadafora C, Awandare GA, Kopydowski KM, Czeg, J, Moch JK, Finberg RW, Tsokos GC, Strute JA (2010) Complement receptor 1 is a sialic acid-independent erythrocyte receptor of Plasmodium falciparum. PLoS Pathog 6(6):e1000968. https://doi.org/10.1371/journal.ppat.1000968

Tadsevir D, Lack G, Bruno R, Riedel S, Scapozza L, Pesezoo R (2006) Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem 49(11):3345–3353. https://doi.org/10.1021/jm0600545

Tayler NM, Boya CA, Herrera L, Moy J, Ng M, Pineda L, Almanza A, Rosero S, Coronado LM, Correa R, Santamaria R, Caballero Z, Durant-Archbold AA, Tidgewell KJ, Balunas MJ, Gerwick WH, Spadafora A, Gutierrez M, Spadafora C (2019) Analysis of the antiparasitic and anticancer activity of the coconut palm (Cocos nucifera L., ARECACEAE) from the natural reserve of Punta Patiño, Darién, PLOS ONE 14(4):e0214193. https://doi.org/10.1371/journal.pone.0214193

Whitman DW, Andrés MF, Martínez-Díaz RA, Ibáñez-Escribano A, Olmeda AS, González-Coloma A (2019) Antiparasitic properties of cantharidin and the blister beetle berberomeloe majalis (Coleoptera: meloloidae). Toxins (Basel) 11(4):234. https://doi.org/10.3390/toxins11040234

World Health Organization (2018). World Malaria Report 2018. https://www.who.int/malaria/publications/world-malaria-report-2018/en/. Accessed Sept 2019

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.